Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Frequency of Clostridium difficile-associated Diarrhea and Relevant Medical Treatment in a Tertiary Care Hospital in Korea

3차 의료기관에서 Clostridium difficile-associated Diarrhea의 발생빈도 및 치료에 관한 연구

  • Kang, Hye-Kyung (Department of Pharmacy, Gyeongsang National University Hospital, Graduate School of Food and Drug Administration, Gyeongsang National University)
  • 강혜경 (경상대학교병원 약제부, 경상대학교 식의약품대학원)
  • Received : 2011.08.22
  • Accepted : 2011.09.19
  • Published : 2011.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

배경: 약물로 인한 Clostridium difficile-associated diarrhea (CDAD)는 널리 알려져 있으며 우리나라에서 항생제와 프로톤 펌프 억제제 소모량을 고려할 때 질환 치료과정에서의 CDAD 발생빈도 및 CDAD 유발 이전에 투여한 약물의 사용빈도와 CDAD의 치료방법을 조사할 필요성이 있다. 방법: 경상대학교 병원에서 2011년 1월부터 6월까지의 입원환자를 대상으로 대변 독소 검사에 의해 CDAD로 판명된 환자의 성별, 연령분포, 질환명, 입원병동, 재발률을 조사하였으며 CDAD 판명이전에 투여한 약제 및 CDAD 판명후 치료약제를 조사하였다. 결과: 연구기간 동안 CDAD 대변 독소 검사 의뢰된 환자수는 1,500명이었으며 CDAD 양성은 111명(9.3%)이었고, 재발은 29명(26.1%)이었다. CDAD를 주소로 입원한 환자는 17명 (15.3%)이었고, 나머지는 입원기간 중에 발생하였다. CDAD 양성인 환자의 연령대는 60대에서 32.4% (36/111명) 이었고, 내과병동에서 34.2%를 나타내었고, 재발률은 외과계 병동에서 41.4%로 가장 높게 나타났다. CDAD 환자의 17% (19/111명)은 항암제 투여 동안 발생하였으며 CDAD 발생 전 사용약물로는 세팔로스포린계 항생제가 162회로 가장 빈번하게 사용 되었으며, 히스타민2 수용체길항제 107회, 스테로이드 82회, 비 스테로이드 항염제 79회, 프로톤 펌프 억제제 77회, 하제 59회, 항암제가 33회 처방되었다. CDAD 치료약제로는 8종의 약제가 241회 처방 되었으며 metronidazole이 99회로 가장 빈번하게 사용되었고, vancomycin이 37회로 나타났다. 결론: 입원환자에 있어서 CDAD양성은 특히 고령의 암환자가 많아 항암제 투여 시에는 CDAD 발생에 주의해야 할것으로 보인다. CDAD의 치료약제로는 metronidazole이 vancomycin 보다 많이 사용되는 것으로 나타났다.

Keywords

References

  1. Quirk M. Clostridium difficile epidemic strain far reaching. Lancet Infect Dis 2006; 6(2): 74.
  2. Musher DM, Logan N, Mehendiratta V. Epidemic Clostridium difficile. N Engl J Med 2006; 354(11): 1199- 203 [author reply 203]. https://doi.org/10.1056/NEJMc053654
  3. Owens RC Jr, Donskey CJ, Gaynes RP, et al., Antimicrobial associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl 1): S19-S31 https://doi.org/10.1086/521859
  4. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med 1998; 49: 375-90. https://doi.org/10.1146/annurev.med.49.1.375
  5. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002; 162: 2177-84. https://doi.org/10.1001/archinte.162.19.2177
  6. Owens RC Jr. Clostridium difficile-associated diseases: An emerging threat to patient safety. Pharmacother 2006; 26(3): 229-311 https://doi.org/10.1592/phco.26.2.229
  7. Gerding DN, Johnson S, Peterson LR, et al., Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16(8): 459-77. https://doi.org/10.1086/648363
  8. Gaynes R, Rimland D, Killum E, et al., Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38(5): 640-5. https://doi.org/10.1086/381551
  9. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficileassociated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990; 162(3): 678-84. https://doi.org/10.1093/infdis/162.3.678
  10. Dial S, Delaney JA, Barkun AN, et al., Use of gastric acid-suppressive agents and the risk of communityacquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-95. DOI: 10.1001/jama.294.23.2989
  11. Shin BM, Kuak EY, Yoo HM, et al., Multicenter study of the prevalence of toxigenic Clostridium difficile in Korea: Results of a retrospective study 2000-2005. J Med Microbiol 2008; 57: 697-701 DOI: 10.1099/jmm.0.4771-0
  12. Lai KK, Melvin ZS, Menard MJ, et al., Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control. Infect Control Hosp Epidemiol 1997; 18(9): 628-32. https://doi.org/10.1086/647687
  13. Olson MM, Shanholtzer CJ, Lee JT Jr, et al., Ten years of prospective Clostridium difficile associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994; 15(6): 371-81. https://doi.org/10.1086/646934
  14. Lee JH, Lee SY, Kim YS, et al., The incidence and clinical features of Clostridium difficile infection; Single center study. Korean J Gastroenterol 2010; 55(3): 175-82 DOI: 10.4166/kjg.2010.55.3.175
  15. Moshkowitz M, Ben BE, Kline Z, et al., Clinical manifestations and outcome of Pseudomembranous colitis in an elderly population in Israel. Isr Med Assoc J 2004; 6(4): 201-4.
  16. Simor AE, Bradley SF, Strausbaugh LJ, et al., Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002; 23(11): 696-703. https://doi.org/10.1086/501997
  17. Weiss K, Bergeron L, Bernatchez et al., Clostridium difficile-associated diarrhea rates and global antibiotic consumption in five Quebec institutions from 2001 to 2004. Int J Antimicrob Agents 2007; 30: 309-14 DOI: 10.1016/l.ijantimicag.2007.05.020
  18. Bouza E, Burillo A, Munoz P. Antimicrobial Therapy of Clostridium difficile-associated diarrhea. Med Clin N Am 2006; 1141-63 DOI:10.1016/j.mcna.2006.07.011
  19. Kutty PK, Woods CW, Sena AC, et al., Risk factors for and estimated incidence of community-associated Clostridium diffcile infection, North Carolina, USA. Emerg Inf Dis 2010; 16(2): 197-204 DOI: 10.3201/ eid1602.090953 http://www.cdc.gov/ncidod/dhqp/pdf/cdiff/ KuttyEID2010.pdf
  20. Manian FA, Aradhyula S, Greisnauer S, et al., Is it Clostridium difficile infection or something else? A casecontrol study of 352 hospitalized patients with new-onset diarrhea. South Med J 2007; 100(8): 782-6. https://doi.org/10.1097/SMJ.0b013e318063e9c5
  21. Obritsch MD, Stroup JS, Carnahan RM, et al., Clostridium difficile-associated diarrhea in a tertiary care medical center. Proc (Bayl Univ Med Cent) 2010; 23(4): 363-7. https://doi.org/10.1080/08998280.2010.11928654
  22. Dalton BR, Lye-Maccannell T, Henderson EA, et al., Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, nonoutbreak hospital setting. Aliment Pharmacol Ther 2009; 29(6): 626-34. https://doi.org/10.1111/j.1365-2036.2008.03924.x
  23. Kang CI, Kim SH, Park WB, et al., Bloodstream infection caused by antibiotic-resistant Gram-Negative Bacilli: Risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49(2): 760-6 DOI: 10.1128/AAC.49.2.760-766.2005
  24. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346(5): 334-9. https://doi.org/10.1056/NEJMcp011603
  25. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26(5): 1027-34 [quiz 35-6]. https://doi.org/10.1086/520276
  26. Trudel JL, Deschenes M, Mayrand S, et al., Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum 1995; 38(10): 1033-8. https://doi.org/10.1007/BF02133974
  27. Elinav E, Planer D, Gatt ME. Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis. Int J Colorectal Dis 2004; 19(3): 273-6 Epub Nov 15, 2003 https://doi.org/10.1007/s00384-003-0541-9
  28. Byun TJ, Han DS, Ahn SB et al., Clinical characteristics and changing epidemiology of Clostridium difficileassociated disease (CDAD). Korean J Gastroenterol 2009; 54(1):13-19 DOI: 10.4166/kjg.2009.54.1.13.
  29. Vaishnavi C. Established and potential risk factors for Clostridium difficile infection. Indian J Med Microbiol 2009; 27(4): 289-300. https://doi.org/10.4103/0255-0857.55436